[ad_1]
The American company presents the first data from its extensive study and is confident of the effect. An emergency permit must be applied for in the US in the next few weeks.
In the global race for a corona vaccine, another research project has reported decisive success. The corona vaccine from the American biotechnology group Moderna showed in an interim analysis an effectiveness of 94.5 percent in protecting against Covid-19. Moderna hopes to apply for an emergency permit in the United States in the coming weeks, the group announced Monday. The effectiveness is greater than the researchers expected. However, it could take months before the vaccine is distributed.
Moderna researchers tested their vaccine by giving some study participants the new vaccine and other placebos (saline). They then looked at the two groups to see how many people get sick. In Moderna’s study, a total of 95 people became ill with Covid-19: five actually vaccinated and 90 subjects receiving placebo. Statistically, the difference between the two groups is significant. Of the 95 illnesses, 11 were serious, all of them in the placebo group, reports the New York Times.
In total, Moderna wants to test the vaccine in its phase three study with 30,000 people; More than 26,650 test subjects (with active ingredient or placebo) have already been vaccinated. However, what is relevant to the study is the number of diseases that are used to make the effectiveness visible compared to the test group. Originally, it was intended to publish a first intermediate balance for 53 diseases among test subjects, but the increasing number of cases today also resulted in a higher number of infections among study participants.
Tal Zaks, Moderna’s chief investigator, sees the results so significantly that the company feels an ethical obligation to be able to deliver the vaccine to the placebo group as quickly as possible. The company could produce between 500 million and 1 billion cans in 2021. Similar to the Pfizer / Biontech vaccine, the modern vaccine must also be transported and stored refrigerated, at around -20 degrees Celsius.
The EU Commission negotiates vaccination doses
Moderna is the second major US pharmaceutical company to report positive data from the pivotal study with a corona vaccine in one week. Last Monday, German biotech company Biontech and its US partner Pfizer announced that their vaccination offers more than 90 percent protection against Covid-19.
The EU Commission is already negotiating a delivery of up to 160 million doses of vaccine with Moderna. The Commission already had a framework agreement for EU member states the week before
Biontech / Pfizer in the purchase of up to 300 million cans
approved. Biontech / Pfizer were the first to publish the first data from their phase three studies. If the study results are positive, they point to a request for approval for your vaccine in late November. The British pharmaceutical company AstraZeneca is also one of the leading companies in the race for a vaccine.
RNA active ingredient
Both Moderna and Biontech rely on packaging of mRNA into fat globules (liposomes) for their vaccines, which should also lead to increased uptake by dendritic (antigen-presenting) cells after vaccination. This increases the immune effect. Biontech is based on the technology of the Polymun company from Klosterneuburg.
Vaccine developer Biontech co-founder Uğur Şahin expects a return to normal by winter 2021. But achieving a high coronavirus vaccination rate before fall is “absolutely essential”, he told the television network on Sunday. British BBC.
Biontech shares, which are primarily listed in the US and traded primarily on the Tradegate platform in Germany, only fell significantly in the red by about ten percent after Moderna’s success report the previous Monday. But then the situation calmed down a bit, most recently articles on Tradegate were still down 3.2 percent.
(Ag./Red)
